Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

What? My project is about exchanging experiences around how to support children's play in Early childhood education and care (ECEC). In Victoria, Australia, the scholars I am visiting have developed a method of supporting childrens play pedagogically,and it is called "conceptual playworld" and they are currently evaluating this evidence based method in order to see how it works and enables children to become skilled players. We are going to analyse their data and learn from them in terms of what works well and what does not seem to work well when the aim is to support 3-6 year old childrens learning and development through play in institutional contexts. I will also inspire my Australian colleagues with regards to how we work to suppert children's play in Danish ECEC. Why? Contrarily to what one might expect, it is difficult to provide rich and stimulating environments for play that all children benefit from. The adult role in stimulating play and supporting children with difficulties in becoming skilful players is complex and requires pedagogical mastery and skilful planning and methodology. Play happens, and some adults are skillful players, however if we want to build a curriculum around children's play we need to make sure that all educators are skillful players who can enable children's play also when it does not happen, and when some children are excluded and kept out of the creative circles of play in the peer-group. This requires scientifically based knowledge and solid pedagogical methods that we are going to develop in the project. How? I arrive at a good time in the project in Victoria, Australia where the research group is collecting data on the merits and pitfalls of the conceptual playworld method. We will analyse this data together and write up the findings to the scientific community. upon my return to DK I'll make use of our experiences from this project in developing and evaluation danish pedagogical pracitices around supporting childrens play in ECEC.

The goal of the FREYA consortium is to iteratively extend a robust environment for Persistent Identifiers (PIDs) into a core component of European and global research e-infrastructures. The resulting FREYA services will cover a wide range of resources in the research and innovation landscape and enhance the links between them so that they can be exploited in many disciplines and research processes. This will provide an essential building block of the European Open Science Cloud (EOSC). Moreover, the FREYA project will establish an open, sustainable, and trusted framework for collaborative self-governance of PIDs and services built on them. FREYA capitalises on the successes of the THOR project and will build on the core services of the existing trusted PID systems of the project partners, developing them in the context of established community-based services and more widely through the EOSC. The FREYA e-infrastructure components will be built on technologies and services that are already well proven. New services, and new PID types, will be introduced and moved up the scale of Technology Readiness Levels, so that the emerging e-infrastructure services are prototyped and positioned for evolution beyond the end of the FREYA project. The vision of FREYA is built on three key ideas: the PID Graph, PID Forum and PID Commons. The PID Graph connects and integrates PID systems to create an information map of relationships across PIDs that provides a basis for new services. The PID Forum is a stakeholder community, whose members collectively oversee the development and deployment of new PID types; it will be strongly linked to the Research Data Alliance (RDA). The sustainability of the PID infrastructure resulting from FREYA beyond the lifetime of the project itself is the concern of the PID Commons, defining the roles, responsibilities and structures for good self-governance based on consensual decision-making.

RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mortality and morbidity, both from uncontrolled disease and treatment associated co-morbidities, like infection and malignancy. This requires the need to stratify patients by their outcome and to tailor immunosuppression based on much deeper knowledge of the mechanisms that control initiation and persistence of the pathogenic immune responses. The RELENT Consortium has been formed to generate this knowledge with the ultimate goal of developing treatments tailored to the specific needs of individual patients. RELENT combines the resources of seven leading European Investigators and two from US and Australia whose expertise is not available elsewhere in the world but necessary for the ambitious work program. Three SMEs will supply specific reagents and translate the results to biomarker development. This will enable RELENT to deliver its four specific research aims, namely to: i) Combine subset analysis of genome wide association studies with classical cell biology to uncover pathways that influence and ii) use multiplexed antigen arrays, whole proteome analysis and rapid mass analysis to identify protein signatures that predict outcome and response to treatment in chronic autoimmune disease. iii) Characterise T and B cell abnormalities that predispose to autoimmunity and infection by studying the ageing immune system in health and disease. iv) Analyse pathogenic effector T cells and their control by macrophages and dendritic cells and the molecules they secrete using in vivo models. We anticipate to identify common mechanisms responsible for the persistence and outcomes in severe autoimmune and inflammatory diseases in females and males and that the results should be rapidly translatable into clinical practice for the benefit of patients.